Sponsors (2)
The bill clarifies and broadens grant coverage to ensure all FDA-approved or -authorized opioid overdose reversal drugs are eligible—helping expand access and rapid adoption of life-saving therapies—while imposing modest additional procurement costs and short-term administrative updates.
People at risk of opioid overdose, and the state/tribal/local public health programs that serve them: federal grant programs will explicitly cover all FDA-approved or -authorized opioid overdose reversal drugs, reducing uncertainty for grantees, enabling quicker procurement and adoption of newer reversal therapies, and improving access to potentially life-saving treatments.
Taxpayers and grant-funded jurisdictions (states, tribes, localities): explicitly covering additional or newer reversal drugs may raise grant-funded procurement costs, increasing federal and/or state spending on overdose reversal supplies.
Federal agencies and grantees: HHS must revise regulations and guidance across grant programs within one year, creating short-term administrative workload and implementation costs for federal staff and for state/tribal/local grantees adapting to updated requirements.
Based on analysis of 2 sections of legislative text.
Requires HHS to use inclusive language in opioid grant regulations and update two grant programs' references to cover any FDA‑approved or authorized opioid overdose reversal drug.
Official title: Ensure references to opioid overdose reversal agents in certain grant programs of the Department of Health and Human Services are not limited to naloxone.
Introduced July 17, 2025 by John Cornyn · Last progress July 17, 2025
Requires the HHS Secretary to make grant program regulations and guidance use inclusive language that covers any FDA‑approved opioid overdose reversal drug for emergency treatment, and to update references in two existing opioid grant programs so they explicitly cover all such drugs or authorized products. Agencies must complete the specified updates within one year after enactment.